Hypertrophic osteoarthropathy effectively treated with zoledronic acid

Clinical Lung Cancer

Volumn 9, Issue 3, 2008, Pages 179-182

  King, Melissa M ^a   Nelson, Douglas A ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Bronchogenic carcinoma; Platelet derived growth factor; Vascular endothelial growth factor

Indexed keywords

CARBOPLATIN; ERLOTINIB; FENTANYL; GEMCITABINE; IBUPROFEN; INDOMETACIN; OXYCODONE; PEMETREXED; ZOLEDRONIC ACID;

ADULT; ANAMNESIS; ARTICLE; BRAIN CANCER; CASE REPORT; CLINICAL EXAMINATION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; HYPERTROPHIC OSTEOARTHROPATHY; LEG PAIN; LEG SWELLING; LUNG ADENOCARCINOMA; PHYSICAL EXAMINATION; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 45849091183     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.027     Document Type: Article

References (30)

1. Martinez-Lavin M, Matucci-Cerinic M, Jajic I, et al. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol 1993; 20:1386-7.
2. Semple T, McCluskie RA. Generalized hypertrophic osteoarthropathy in association with bronchial carcinoma; a review, based on 24 cases. Br Med J 1955; 1:754-9.
3. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003; 25:2669-708.
4. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in metastases in breast cancer with adjuvant clodronate treatment. N Eng J Med 1998; 339:357-63.
5. Suzuma T, Sakurai T, Yoshimura G, et al. Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anti-Cancer Dr 2001; 12:731-4.
6. Amital H, Applbaum YH, Vasiliev L, et al. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23:330-2.
7. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-87.
8. Zometa® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003.
9. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91:1191-200.
10. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest 1998; 114:1535-7.
11. Silveira LH, Martinez-Lavin M, Pineda C, et al. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000; 18:57-62.
12. Heldin CH, Westermark B. Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor. Physiol Rev 1999; 79:1283-1316.
13. Alvarez RH, Kantarjian HM, Cortes JE. Biology of Platelet-Derived Growth Factor and Its Involvement in Disease. Mayo Clin Proc 2006; 81:1241-57.
14. Silveri F, De Angelis R, Argentati F, et al. Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 1996; 15:435-9.
15. Landrum ML, Ornstein DL. Hypertrophic osteoarthropathy associated with metastatic phloxes tumor. Am J Clin Oncol 2003; 26:146-50.
16. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997; 77:431-6.
17. Dvorak HF. Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target fot Diagnosis and Therapy. J Clin Oncol 2002; 20:4368-80.
18. Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocr Rev 2004; 25:581-611.
19. Abe Y, Kurita S, Ohkubo Y et al. A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 2002; 22:3485-8.
20. Olan F, Portela M, Navarro C, et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy: correlation with disease activity. J Rheumatol 2004; 31:614-6.
21. Rosenthall L, Kirsh J. Observations of radionuclide imaging in hypertrophic pulmonary osteoarthropathy. Radiology 1976; 120:359-62.
22. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma. N Engl J Med 1996; 334:488-93.
23. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone lesions. N Engl J Med 1996; 335:1785-91.
24. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-21.
25. Garske LA, Bell SC. Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 2002; 21:1363-4.
26. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate Induces Modifications of Circulating Angiogenic Factors in Cancer Patients. Clin Cancer Res 2002; 8:1080-4.
27. Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004; 100:36-43.
28. Santini D, Vincenzi B, Galluzo S et al. Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients. Clin Cancer Res 2007; 13:4482-6.
29. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients. Oncology 2005; 69:35-43.
30. Thompson MA, Warner NB, Hwu WJ. Hypertrophic Osteoarthropathy Associated with Metastatic Melanoma. Melanoma Res 2005; 15:559-61.